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One of the most significant decisions we
face as scientists comes at the end of our
formal education. Choosing between in-
dustry and academia is easy for some,
incredibly fraught for others. The author
has made two complete cycles between
these career destinations, including on the
one hand 16 years in academia, as grad
student (twice, in biology and in computer
science), post-doc, and faculty, and on the
other hand 19 years in two different
industries (computer and pharmaceutical).
The following rules reflect that experience,
and my own opinions.
Rule 1: Assess Your
Qualifications
If you are a freshly minted Ph.D., you
know that you will need a good post-doc
or two before you can be seriously
considered for a junior faculty position. If
you’re impatient, you might be thinking of
industry as a way to short-circuit that long
haul. You should be aware that companies
will strongly consider your post-doctoral
experience (or lack thereof) in determining
your starting position and salary. While
you may not relish extending your inden-
tured servitude in academia, any disad-
vantage, financial and otherwise, can
quickly be made up in the early years of
your career in industry. In other words,
trying to get off the mark quickly is not
necessarily a good reason to choose
industry over academia.
On the other hand, you may have
completed an undergraduate or Master’s
program with a view to going to industry
all along, with never a thought of an
academic career. You should still consider
the point of the previous paragraph. While
abbreviated ‘‘practical’’ bioinformatics
training programs can be excellent, a
Ph.D. is a significant advantage in all but
the most IT-oriented positions in industry,
at least at the outset. This is not to
discourage anyone from embarking on a
fast-track-to-industry program if their
heart is in it, but be aware that the further
you climb the educational ladder, the
higher and faster you can start when you
step across to the business ladder, and the
better you will compete for a job in the
first place. The days are long past when
bioinformaticists were in such short supply
that any qualification would do.
If you are an old hand and have already
notched up a post-doc or two, take stock of
your star power. This unspoken but
universally understood metric encompass-
es such factors as whom you’ve trained
with, where you’ve published (and how
much), and what recent results of yours
are on everyone’s lips. If you are fortunate
enough to have significant capital in this
department, then the world may be your
oyster, but you still need to consider where
you will get the greatest leverage. While
your stardom may be less taken for
granted in industry, my feeling is that
academia is a better near-term choice in
such circumstances. Consider that it was
in academia that you achieved the success
you own thus far, so you obviously ‘‘get
it.’’ The simple fact is that academia is
rather more of a star system (as in
Hollywood) than is industry.
Finally, if you count among your
qualifications a stint in industry already,
as an intern or perhaps as part of a
collaboration, you will not only be in a
better position to compete for a perma-
nent job, but you will be much better
prepared to make the decision facing you.
Stated another way, if you are seriously
considering industry as a career path, you
should probably have already taken ad-
vantage of the many opportunities out
there to dip your toes in the water.
Rule 2: Assess Your Needs
Intakingstockofyourneeds,andperhaps
those of your family, a decent living is
generally at or near the top of the list.
Salaries are still higher in industry, though
thegapisnotnearlysowideasitoncewas.If
you need a quick infusion of cash, compa-
nies may offer signing bonuses, though
again these were more common when
bioinformatics was a rarer commodity.
Industry offers forms of compensation
unavailable in academia, and you will
need to consider how to value them
relative to your present and future needs.
Despite recent bad press, bonus systems
are often part of the equation, and
depending on your entry point they may
constitute a significant percentage of total
compensation. There is a tendency among
academics to discount bonus programs in
their comparison shopping, sometimes to
zero, and this is a mistake. Bonuses are
considered core aspects of compensation
in most companies, and though they
always have a performance-based multi-
plier, the base levels have historically been
fairly dependable. That said, these are
tough times in industry, and there are no
guarantees. Your best strategy is to
understand the reward system thoroughly,
ask for historical data, and avoid compar-
ing only base salaries unless you are
extraordinarily risk-averse.
Share options are another matter.
While in the past these were very attrac-
tive, and fruitful in practice, most industry
types will tell you frankly that any options
they’ve received in the past decade are
deep underwater and a deep disappoint-
ment. Many consider pharma shares (and
therefore options) to be a bargain at the
moment, but that’s between you and your
financial adviser to assess. In any case, it is
not a short-term consideration, since
options typically take several years to vest.
If you are looking at biotech, however,
share options and similar ownership
schemes need to be a key consideration,
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assuming risk—more on that below.
Finally, you may have more specific
needs to consider, such as a spouse also in
need of a job. The two-body problem has
always been tougher in academia than in
industry, and probably always will be. If
you are both academics, note that industry
often has good contacts with local univer-
sities, and can facilitate interviews. Being a
star certainly helps, so don’t be afraid to
negotiate. In fact, a general rule of thumb
is that it never hurts to make your specific
needs known, within reason. Academia
will try to accommodate them as a
community, while on the other hand
business (particularly large, diversified
companies) may have resources to address
them that you wouldn’t have expected.
Nobody wants to hear a peremptory
demand, but if a company wants you, be
sure to let them know anything that might
offer them a way to attract you.
Rule 3: Assess Your Desires
There are needs, and then there are
desires. Do you want riches? Fame? A life
at the frontiers of knowledge? The hurly-
burly of the business world? How do you
really feel about teaching, publishing,
managing, interacting, traveling, negotiat-
ing, collaborating, presenting, reporting,
reviewing, fundraising, deal-making, and
on and on? Though it may seem obvious,
this is a good time to decide what really
drives you.
First, the obvious. Do you want to
teach? If lecturing is in your blood, your
decision is made, although if a smattering
will suffice you may have the option from
within industry of an adjunct academic
appointment. (By the same token, if you
are not so enchanted with lecturing,
grading, tutoring, etc., there are often
options for research track professorships
that minimize teaching duties.) Do you
want to publish? While it will always be
‘‘publish or perish’’ in academia, it is
certainly possible to grow your CV in
industry, and it can even enhance your
career, depending on the company. How-
ever, it might be largely on your own time,
and you will likely encounter restrictions in
proprietary matters, though in practice
you can generally find ways to work within
them. Ask about publication at the
interview, both policies and attitudes,
and watch out for any defensiveness.
An important question, surprisingly
often overlooked, is how you want to
actually spend your time, day by day and
hour by hour. In academia, you will
immediately be plunged into hands-on
science, and your drivers will be to start
out on your career by getting results,
publishing, networking, and building your
reputation with a view to impressing your
tenure committee. A career in industry
may put more of an early emphasis on
your organizational aptitude, people skills,
powers of persuasion, ability to strategize
and execute to plan, etc.; in terms of
growing your reputation, your audience
will be the rather narrower community of
your immediate management. A some-
what more cynical view would be that in
business you will spend seemingly endless
hours in meetings and writing plans and
reports, while in academia you will spend
all that time and more in grantsmanship—
in this regard, you must pick your poison.
Finally there is the elephant-in-the-
room question: Do you want to make
money, or to help people? This is, of
course, a false dichotomy, but many
people consciously or unconsciously frame
the decision in just this way, and you had
best deal with it. Try thinking of it not so
much in terms of the profit motives of the
respective institutions, but in terms of the
people with whom you would spend your
career. You should have encountered a
good sampling of scientists from industry
during meetings, internships, collabora-
tions, interviews, etc. (or in any case you
should certainly try to do so before making
judgments). If you are left in any doubt as
to their ethics or sincere desire to relieve
human suffering as efficiently as possible,
or if you feel these are somehow trumped
by the corporate milieu, then by all means
choose academia—but only after applying
analogous tests to the academics you
already know well. In my experience,
business doesn’t have a monopoly on
greed, nor are humanitarian impulses
restricted to academia. That said, in the
final analysis you must be comfortable
with your role in the social order and not
finesse the question.
Rule 4: Assess Your Personality
Not surprisingly, some personality types
are better-suited to one environment or
the other. Raw ambition can be viewed as
unseemly in either case, but there is more
latitude for it in industry, and greater
likelihood of being recognized and re-
warded sooner if you are ‘‘on the go.’’ In
fact, one of the clearest differences be-
tween academia and industry are their
respective time constants. Although the
pace of academia may have quickened of
late, it is still stately by comparison with
industry, and much more scheduled (so
many years to tenure, so many months to
a funding decision, etc.). If you are
impatient, industry offers relatively fast-
paced decision-making and constant
change. If you thrive more under struc-
tured expectations, academia would be
better for you, for although industry has all
the trappings of long-range strategies and
career planning, the highly reactive envi-
ronment means these are more honored in
the breach. For one thing, reorganizations
are common, and in the extreme case
mergers (I have experienced two) can reset
everything, for good or ill, and devour
many months.
This is not to say that all is chaos—
industry certainly favors a goal-directed
personality, but with plenty of flexibility.
On the other hand, flexibility is more the
hallmark of academic research, where
you will have the opportunity to follow
w h e r e v e rt h es c i e n c el e a d s ,o n c ey o ua r e
running your own shop. In industry, the
flexibility is more of the conforming sort,
since you won’t be able to investigate
every promising lead and change your
research direction at will. In academia,
diverging from the Specific Aims of a
grant may be a problem when the time
comes to renew, but the risk is yours, as
is the reward. In industry, you can make
the case for a new program of research,
but the decision is management’s and
will be guided by business consider-
ations. The ‘‘lone wolf’’ or ‘‘one-person
band’’ may be increasingly rare in
academia in an age of collaboration,
but it is unheard of in industry, where
being able to work in teams with
specialized division of labor is essential.
It should be apparent, as well, that
mavericks and quirky personalities tend
to do better in academia.
The pecking order in industry is deeper
and more pyramidal than in academia,
and you might end up languishing in a pay
grade (or feel like you are), but there are
usually plenty of opportunities for lateral
moves and a variety of experiences—not
to mention that it’s easier to switch
companies than colleges. In industry, one
does need to be able to thrive in a
hierarchy; you will always answer to
someone, though the degree to which
you are monitored will vary. By the same
token, if your personality is such that
climbing a management ladder and as-
suming steadily greater responsibility suits
you, industry is built for that, and plenty of
management training is on offer in larger
companies. Learning to manage is much
more hit-or-miss in academia; opportuni-
ties to lead large organizations are rare
(and to manage them actively rather than
by consensus, rarer still).
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taker, biotechs and/or startups may fit you
to a tee. These are the wild and wooly end
of the industry spectrum, and the risks and
rewards are well-known. You will work
longer hours than in large pharma, and
maybe even more than in academia. You
will most likely share more in ownership,
and learn entrepreneurial skills that will
serve you well, once the bug has bitten.
Bear in mind the very common pattern of
faculty spinning off startups or otherwise
participating in boards and the like, not to
mention staking out intellectual property
(shared with their university); thus, you
may well be able to scratch this itch from
the vantage of academia as well.
A final word about politics. Whether
you are an enthusiastically political ani-
mal, or abhor this aspect of the human
condition, you will encounter plenty of
politics in both academia and industry.
The flavors differ, to be sure. As a student
you doubtless heard the cliche ´s about
tedious academic committees and under-
handed deans, but you have probably had
more exposure to the realities behind those
stories than the corresponding ones about
the dog-eat-dog corporate world. Compa-
ny politics, I would hazard to say, are
more transparent—the maneuvering more
open and the motives more apparent. The
results are often more life-altering, unbuf-
fered by tenure and academic convention.
Again, it is a matter of taste, but in my
opinion the differences are overblown, for
the simple reason that people are the same
everywhere, in both environments gov-
erned by an underlying sense of fair play,
but also occasional opportunism.
Rule 5: Consider the
Alternatives
As I’ve suggested, the choice you face is
far more fine-grained than simply that
between industry and academia. Industry
is a spectrum, from large pharma to
mature biotech to startup. By the same
token, the academic side has at one
extreme the research powerhouses, where
you will be judged by volume of grants,
and at the other the teaching institutions,
which may not even have graduate
departments. Unless you are very sure of
yourself, you’d be well-advised to consider
the full range, given the competition you
may face.
Also, don’t neglect other careers that
may value your training. If you love the
language, consider science journalism,
either writing or editing—Science and
Nature have large staffs, and you will often
encounter them and representatives of
other journals at the same scientific
meetings you attend. The same is true of
government agencies such as the NIH,
NSA, DOE, and so forth, where grants
administration is very actively tied to
research trends and can be an entre ´e into
the world of science policy. There are
many more such positions when founda-
tions, interest groups, and other private
funding bodies are included. If you have a
knack for business, many management
consulting firms have scientific and tech-
nical consulting arms that value Ph.D.s
and offer intensive training opportunities,
and, though it may not be attractive at the
moment, a career as a financial analyst
specializing in biotech is yet another
possibility.
Rule 6: Consider the Timing
The current business environment can-
not help but be among your consider-
ations. Pharma has certainly been con-
tributing to the unemployment rolls of
late. Corporate strategies, which used to
be very similar across the sector, have
started to diverge, so that some companies
are divesting bioinformatics at the same
time that others are hiring computational
types disproportionately as they place
more of an emphasis on mathematical
modeling, systems approaches, pharmaco-
genomics, drug repurposing, and the like.
Overall, though, the industry trend has
been to shrink R&D, and this may well
continue through a round of consolida-
tion, with several mega-mergers now
under way. As noted above, mergers are
times of upheaval, carrying both risk and
opportunity, and usually a period in limbo
as well. At the same time, it is worth
bearing in mind that a corollary of
downsizing is outsourcing, so that there
may be new opportunities for startups and
even individual consultants.
For much of the last decade, academia
has also been in the doldrums, as NIH
budgets have effectively contracted. As I
write this, things are definitely looking up,
with prospects for renewed funding of
science and even near-term benefits to the
NIH and NSA from the Obama stimulus
package. Whether universities will respond
proportionately with faculty hiring, given
the losses in their endowment funds and
cutbacks in salaries and discretionary
spending, remains to be seen. There is a
lot of slack to be taken up, and in
particular a backlog of meritorious grant
applications that are now being reconsid-
ered. Nevertheless, on balance, an aca-
demic career has to be somewhat more
promising today than a year ago, and a
career in pharma rather less so, in the
opinion of the author.
Rule 7: Plan for the Long Term
Having noted the current situation in
Rule 6, it’s important also to say that a
career decision should be made with the
long haul in mind. The business cycle will
eventually reverse itself, and while the
business model may need to change
irrevocably, the aging population alone
dictates that healthcare will be an increas-
ing global priority. Likewise, history shows
that growth in government funding for
science waxes and wanes, with a time
constant somewhat longer than a decade.
Trying to optimize a career decision based
on current conditions is a bit like trying to
time the stock market—you are sure to be
overtaken by events.
One approach is to choose some
reasonably long time frame, perhaps a
decade, and ask yourself whether you’d be
content to have lived through the average
ups and downs you’d experience in a given
job over that period. In academia, that
would include a tenure decision (rate your
chances), a lot of grant applications with
mixed success at best, and maybe some
great students and really significant scien-
tific contributions. In pharma or large
biotech, it would encompass a couple of
promotions, your own group and maybe a
department, at least one merger or other
big disruption, and several rounds of
layoffs. In small business, it might include
a failed startup (or two, or three), an IPO if
you’re lucky, and a lucrative exit strategy
or long-term growth if you’re really lucky.
If you game these scenarios with various
probabilities, and use your imagination, it
just might become clear which ones you
have no stomach for, and which ones
really hold your interest.
Rule 8: Keep Your Options Open
Job-hopping is much more prevalent
now than in days of yore, and you should
consider this in your scenarios. In industry,
there is little stigma attached to changing
employers, and if you can tolerate the
relocation and/or want to see the world, it
is a more or less standard way to advance
your career by larger-than-usual incre-
ments. This stratagem is far from un-
known in academia, but perhaps a bit
trickier to execute, though of course it is de
rigueur if you fail to get tenure.
Of greater interest is the question of
moving between academia and industry.
From the former to the latter is fairly easy,
but the reverse is not as common, for a
variety of reasons. Superstar academics in
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industry, to which they are often exposed
through consulting or scientific advisory
boards. There are multiple examples of
senior academics taking over major R&D
organizations in industry, sometimes or-
ders of magnitude larger than anything
they managed in academia, and you might
even consider this well-trod path as a
career goal from the outset.
It is not impossible to return to
academia from industry, particularly if
you were already quite prominent when
you left, but if you start your career in
industry you may be at a disadvantage
unless you go to great lengths to maintain
an academic-style publication record and
CV. Important exceptions would be if the
work that you did in industry was
particularly novel and/or high-profile, or
if your business experience is valued in the
post you seek. Examples of the latter might
be faculty positions with a prominent
management component (centers, insti-
tutes, core facilities, and the like), or an
interface role back to industry, or perhaps
a joint business school appointment.
Rule 9: Be Analytic
Approach the decision with the analytic
skills you’ve learned to apply to scientific
questions. Gather data from all available
sources and organize it systematically.
When you interview, don’t just impress,
but get impressions; record everything
down to your gut feelings. Do some
bibliometric or even social network anal-
yses of your potential colleagues. Check
the industry newsletters and blogs, albeit
with a grain of salt, to get a sense of the
mood around R&D units (not to be
confused with manufacturing, sales and
marketing, or other divisions, which may
have completely different cultures within
the same company).
You might even try out some decision
theoretic methodologies, such as decision
matrices and Bayesian decision trees, or
run simulations on the scenarios of Rule 7.
I recommend taking a look at expected
utility theory and prospect theory, for an
interesting quantitative excursion. But
honestly, these suggestions are just a more
sophisticated informatics version of the
classic advice to ‘‘make a list of pros and
cons,’’ which always makes one feel a little
more in control.
Rule 10: Be Honest with
Yourself
Another homily: Now, if ever, is the
time to be honest with yourself. Take a
hard look at your qualifications, with as
much objectivity as you can muster, and
use these rules to decide where you would
be best-suited and positioned for success.
But even more importantly, deal with your
emotional responses to industry and aca-
demia. If something is nagging at you,
tease it out into the open, and try to decide
if it is well-founded or not; if you can’t
decide, then you have to acknowledge it,
and realize that it may not go away in the
future either.
Finally, try to keep some perspective.
Your career choice is important, but not
irrevocable, and there are more conse-
quential things in life. Don’t let the
decision process ruin what should be an
exciting time for you.
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